Lipella Pharmaceuticals (Lipella Pharmaceuticals) Debt-to-Equity : 0.05 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Lipella Pharmaceuticals Debt-to-Equity?

Lipella Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.09 Mil. Lipella Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.02 Mil. Lipella Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $2.56 Mil. Lipella Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lipella Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

LIPO' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.86 Med: 0.09 Max: 0.84
Current: 0.05

During the past 4 years, the highest Debt-to-Equity Ratio of Lipella Pharmaceuticals was 0.84. The lowest was -3.86. And the median was 0.09.

LIPO's Debt-to-Equity is ranked better than
72.94% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs LIPO: 0.05

Lipella Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Lipella Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipella Pharmaceuticals Debt-to-Equity Chart

Lipella Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.84

0.20

0.09

0.04

Lipella Pharmaceuticals Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial									0.10	0.04	0.07	0.04	0.05

Competitive Comparison of Lipella Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Lipella Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipella Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's Debt-to-Equity falls into.

Lipella Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lipella Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.089	+	0.047)	/	3.144
	=	0.04

Lipella Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.092	+	0.024)	/	2.561
	=	0.05

Lipella Pharmaceuticals (NAS:LIPO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lipella Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lipella Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipella Pharmaceuticals (Lipella Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipella Pharmaceuticals Inc (NAS:LIPO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208

Website

https://www.lipella.com

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's lead product candidates include LP-10 and LP-310.

Executives

Lori Birder	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Daniel R Cohen	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Byong Kim	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Jonathan H Kaufman	director, 10 percent owner, officer: See Remarks	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Ryan Pruchnic	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Douglas Johnston	officer: Chief Financial Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Michael B Chancellor	director, 10 percent owner, officer: Chief Medical Officer	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208
Naoki Yoshimura	director	C/O LIPELLA PHARMACEUTICALS INC., 7800 SUSQUEHANNA ST., SUITE 505, PITTSBURGH PA 15208